The effects of drugs that treat Alzheimer’s, cancer and other illnesses are often limited by the blood-brain barrier. A small study suggests a way forward.
Tag: Aduhelm (Drug)
-
FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
-
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
-
What A.L.S. and Alzheimer’s Drug Approvals Have in Common
How to balance patient’s needs with their safety.